|
|
|
|
The Versatility of Gleevec:
An Option for More Cancer Patients
Two years ago, when US Food and Drug Administration approved GleevecTM (imatinib mesylate) for the treatment of chronic myeloid leukemia (CML), an uncommon but life-threatening blood cancer, the drug was hailed as a breakthrough. Unlike many other drugs celebrated as breakthroughs, Gleevec has largely fulfilled its promise.
Read Article
|
|
|